KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Leases (2019 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Operating Leases for 7 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 16.14% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a 16.14% decrease, with the full-year FY2025 number at $6.4 million, down 16.14% from a year prior.
  • Operating Leases was $6.4 million for Q4 2025 at Xenon Pharmaceuticals, down from $6.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $10.4 million in Q1 2023 to a low of $2.6 million in Q3 2021.
  • A 5-year average of $7.5 million and a median of $7.8 million in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: skyrocketed 1260.64% in 2021, then fell 20.39% in 2024.
  • Xenon Pharmaceuticals' Operating Leases stood at $7.7 million in 2021, then increased by 29.99% to $9.9 million in 2022, then fell by 3.45% to $9.6 million in 2023, then dropped by 20.39% to $7.6 million in 2024, then fell by 16.14% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Operating Leases are $6.4 million (Q4 2025), $6.8 million (Q3 2025), and $7.3 million (Q2 2025).